logo-loader
Bristol-Myers Squibb Co

Bristol-Myers beats 1Q estimates, guides higher for full-year 2018 on drug approvals

The drug giant reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts was US$0.85 per share on revenue of US$5.2bn

pills
Bristol raised its earnings guidance for 2018 to US$3.35 to US$3.45

Bristol-Myers Squibb (NYSE:BMY), the pharmaceutical giant, beat Wall Street’s estimates on first-quarter profits, matched on revenues and guided higher on its full-year 2018 earnings forecast.

Bristol-Myers Squibb reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts came to US$0.85 per share on revenue of US$5.2bn.

Bristol also fared well in the quarter on the drug development front and its results from a clinical trial of Opdivo, its immunotherapy drug as well as another of its cancer-fighting medicines Yervoy cheered investors. When taken in combination, the pair of drugs cut the risk of cancer progression or death in clinical trials by 42% when compared to chemotherapy.

The combination of Opdivo plus Yervoy has been approved in the U.S. for patients with intermediate and poor risk advanced renal cell carcinoma.

READ: Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

“We … obtained FDA approval for Opdivo plus Yervoy in renal cell carcinoma, a disease with high unmet need which represents an important opportunity for the company,” said Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb. “I am confident that strong commercial execution, upcoming Phase 3 readouts across our oncology pipeline and continued strategic use of business development position us well for future growth.”

Bristol’s revenue for the quarter jumped 5% to US$5.19bn, up from US$4.93bn in the same period last year.

Bristol also managed to increase its earnings guidance for 2018 to US$3.35 to US$3.45 per share, up from its previous forecast of US$3.15 to US$3.30 per share and higher than Wall Street’s estimate of US$3.22 per share. 

In pre-market trade, Bristol-Myers Squibb shares edged up slightly to US$52.20.

Quick facts: Bristol-Myers Squibb Co

Price: $47.63

Market: NYSE
Market Cap: $77.91 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Empower Clinics begins trading on the OTCQB under the ticker...

Empower Clinics (CSE: CBDT-OTC: EPWCF) Chairman and CEO Steven McAuley sat down with Steve Darling from Proactive Vancouver to share news the company is now trading in the United States. Empower is now listed on the OTCQB market and McAuley talks about what this means for the company and...

3 hours, 21 minutes ago

2 min read